Insider · CIK 0002009350
Tai Sandi See
Files at LXEO (Lexeo Therapeutics, Inc.). First filing May 20, 2025, latest Nov 20, 2025.
Tai Sandi See files SEC Form 4 as officer at LXEO (Lexeo Therapeutics, Inc.). Since May 20, 2025, Tai Sandi See has reported 0 open-market buys worth $0 and 4 open-market sells worth $41k, the latest filed on Nov 20, 2025.
A track record needs three past buys with six months of prices behind them; Tai Sandi See has 0, so none is measured yet.
The newest scored trade: sold $3,578 of LXEO on Nov 18, 2025, filed Nov 20, 2025, scored 30 (weak). In the last 12 months: 0 buys worth $0 and 2 sells worth $38k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
LXEO: Lexeo Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | Lexeo Therapeutics, Inc. | $3,578 386 shares | -1% | +413% from low-9% from high | |
| 36Weak | Lexeo Therapeutics, Inc. | $35k 3,888 shares | -6% | +435% from low-14% from high | |
| 30Weak | Lexeo Therapeutics, Inc. | $1,783 382 shares | -1% | +175% from low-56% from high | |
| 30Weak | Lexeo Therapeutics, Inc. | $1,018 367 shares | -1% | +81% from low-71% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 18, 2025 | LXEO Lexeo Therapeutics, Inc. | 382 0.00% of outstanding | $1,783 | Aug 18, 2025 | none |
| May 16, 2025 | LXEO Lexeo Therapeutics, Inc. | 367 0.00% of outstanding | $1,018 | May 16, 2025 | $6,558 |
| Feb 19, 2025 | LXEO Lexeo Therapeutics, Inc. | 1,486 0.00% of outstanding | $6,558 | Feb 19, 2025 | none |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 18, 2025 | LXEO Lexeo Therapeutics, Inc. | SOpen-market sale Common Stock | -386 | $9.27 | $3,578 | 65,476 | Nov 20, 2025 |
| Oct 15, 2025 | LXEO Lexeo Therapeutics, Inc. | AGrant or award Common Stock | +10,890 | $0.00 | $0 | 69,750 | Oct 17, 2025 |
| Oct 17, 2025 | LXEO Lexeo Therapeutics, Inc. | SOpen-market sale Common Stock | -3,844 | $8.94 | $34k | 65,906 | Oct 17, 2025 |
| Oct 17, 2025 | LXEO Lexeo Therapeutics, Inc. | SOpen-market sale Common Stock | -44 | $9.56 | $421 | 65,862 | Oct 17, 2025 |
| Aug 18, 2025 | LXEO Lexeo Therapeutics, Inc. | SOpen-market sale Common Stock | -382 | $4.67 | $1,783 | 58,860 | Aug 20, 2025 |
| May 16, 2025 | LXEO Lexeo Therapeutics, Inc. | SOpen-market sale Common Stock | -367 | $2.77 | $1,018 | 59,242 | May 20, 2025 |
| Mar 14, 2025 | LXEO Lexeo Therapeutics, Inc. | AGrant or award Common Stock | +5,720 | $2.61 | $15k | 59,609 | Apr 9, 2025 |
Questions about Tai Sandi See
Answered from the filings on this page, as of the latest one.
Is Tai Sandi See buying or selling?
In the last 12 months Tai Sandi See reported 0 open-market buys worth $0 and 2 open-market sells worth $38k on SEC Form 4; the latest was sold $3,578 of LXEO on Nov 18, 2025. Grants, option exercises and tax withholding are not counted.
How did Tai Sandi See's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Tai Sandi See has 0.
Where does Tai Sandi See file Form 4?
Tai Sandi See has filed Form 4 at LXEO (Lexeo Therapeutics, Inc.) as Chief Development Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.